MaxCyte, a cell-engineering company, announced it will acquire Akron Bio, a supplier of GMP-grade reagents for cell therapy manufacturing, for $151.8 million. This acquisition is expected to nearly double MaxCyte's revenue base by adding Akron's $28 million projected 2026 revenue and expanding MaxCyte's presence across the cell therapy workflow. The deal enhances recurring revenue, commercial-stage exposure, and accelerates MaxCyte's path to profitability, supported by a new $75 million credit facility. The transaction is expected to close by the end of 2026, strengthening MaxCyte's role in the growing cell therapy market.
MaxCyte's acquisition of Akron Bio provides context for readers following cell therapy developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 17:11 WIB: out of 150 priced US health stocks, 70 rose and 65 fell. MRVI traded at USD 7.83 with a 1-day change of -2.37%, and BNGO saw a 1-day change of +1.72% with a typical hold time of 53 days and 100% sell order activity on Pluang.
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Wix reported Q3 2026 earnings per share of $1.42, surpassing the $1.40 estimate, and revenue of $570.2 million, exceeding the $566.3 million forecast. Bookings grew 11% to $573 million, with revenue up 13%, driven mainly by Base44's strong performanc...
